Shots:  

• STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease
• With the acquisition- STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology- already launched in Nordic countries
• Levodopa- carbidopa and entacapone infusion therapy is inserted in the small intestine through a discreet- wearable pump. The infusion is approved in Sweden- Denmark- Norway- and Finland- while STADA is currently submitting approval applications to launch the therapy in multiple EU markets

­ Ref: STADA | Image: S